Gish enVisions hitting $10 mil. in annual hollow fiber oxygenator sales in 18-24 months.
This article was originally published in The Gray Sheet
GISH ENVISIONS REACHING $10 MIL. HOLLOW FIBER OXYGENATOR ANNUAL SALES LEVEL in 18-24 months, the firm states. Gish began full-scale marketing of the Vision oxygenator, used to replace the function of the lungs during open-heart surgery, Jan. 26 at the Society of Thoracic Surgeons meeting in New Orleans. As Gish Biomedical's first oxygenator, the Vision completes the company's cardiovascular heart/lung bypass circuit offerings. The device lists for $400 alone, or $450 with a hard shell venous reservoir.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.